GPT-Rosalind
GPT-Rosalind is a purpose-built frontier reasoning model developed by OpenAI to accelerate scientific research across biology, drug discovery, and translational medicine. It is designed specifically for life sciences workflows, where researchers must navigate large volumes of literature, experimental data, and specialized databases to generate and validate new ideas. It combines deep domain understanding in areas such as chemistry, genomics, protein engineering, and disease biology with advanced tool-use capabilities, allowing it to interact with scientific databases, analyze experimental outputs, and support complex, multi-step reasoning tasks. It can assist with evidence synthesis, hypothesis generation, literature review, sequence interpretation, and experimental planning, helping scientists move faster from raw data to actionable insights. GPT-Rosalind transforms complex, time-intensive research processes into more efficient AI-assisted workflows.
Learn more
AWS HealthOmics
Securely combine the multiomic data of individuals with their medical history to deliver more personalized care. Use purpose-built data stores to support large-scale analysis and collaborative research across entire populations. Accelerate research by using scalable workflows and integrated computation tools. Protect patient privacy with HIPAA eligibility and built-in data access and logging. AWS HealthOmics helps healthcare and life science organizations and their software partners store, query, and analyze genomic, transcriptomic, and other omics data and then generate insights from that data to improve health and advance scientific discoveries. Store and analyze omics data for hundreds of thousands of patients to understand how omics variation maps to phenotypes across a population. Build reproducible and traceable clinical multiomics workflows to reduce turnaround times and increase productivity. Integrate multiomic analysis into clinical trials to test new drug candidates.
Learn more
BenevolentAI
BenevolentAI is an AI-enabled drug discovery platform and scientific technology company that unites advanced artificial intelligence, machine learning, and domain-specific science to accelerate the discovery, design, and development of new medicines for complex diseases by making sense of vast, diverse biomedical data and generating actionable scientific insights faster than traditional methods. Its proprietary Benevolent Platform ingests and harmonizes structured and unstructured biomedical information, including literature, genomics, clinical information, and multi-omics data, into a comprehensive knowledge graph, enabling scientists to reason across biological systems, generate hypotheses, predict novel drug targets, and design candidate molecules with higher confidence and lower failure rates.
Learn more
Nygen
Nygen is a cloud-based single-cell RNA-seq (scRNA-seq) and multi-omics data analysis and discovery platform designed to let researchers upload, explore, visualize, analyze and interpret complex cellular datasets with an intuitive, no-code interface that supports drag-and-drop workflows and advanced scientific analysis without requiring programming expertise; it combines Nygen Analytics for rapid, reproducible scRNA-seq exploration with collaborative dashboards and publication-ready outputs, Nygen Database for accessing and hosting curated single-cell datasets to accelerate research and comparative studies, and Nygen Insights, an AI-augmented tool that delivers highly accurate cell annotations, in-depth disease impact analysis and tailored biological insights; it supports a wide range of data formats, integrates public data, enables secure cloud-based collaboration, and provides features like literature-linked evidence and biomarker-focused analyses.
Learn more